Segui
Castellani
Castellani
natinal cancer institute genoa
Email verificata su istge.it
Titolo
Citata da
Citata da
Anno
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory
L Mortara, P Castellani, R Meazza, G Tosi, A De Lerma Barbaro, ...
Clinical cancer research 12 (11), 3435-3443, 2006
7932006
Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED‐B domain of fibronectin
L Borsi, E Balza, M Bestagno, P Castellani, B Carnemolla, A Biro, ...
International journal of cancer 102 (1), 75-85, 2002
4242002
Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer
M Santimaria, G Moscatelli, GL Viale, L Giovannoni, G Neri, F Viti, ...
Clinical Cancer Research 9 (2), 571-579, 2003
3962003
The fibronectin isoform containing the ED‐B oncofetal domain: a marker of angiogenesis
P Castellani, G Viale, A Dorcaratto, G Nicolo, J Kaczmarek, G Querze, ...
International journal of cancer 59 (5), 612-618, 1994
3961994
Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix
B Carnemolla, L Borsi, E Balza, P Castellani, R Meazza, A Berndt, ...
Blood, The Journal of the American Society of Hematology 99 (5), 1659-1665, 2002
3552002
Selective targeted delivery of TNFα to tumor blood vessels
L Borsi, E Balza, B Carnemolla, F Sassi, P Castellani, A Berndt, ...
Blood 102 (13), 4384-4392, 2003
3072003
A high-affinity human antibody that targets tumoral blood vessels
L Tarli, E Balza, F Viti, L Borsi, P Castellani, D Berndorff, L Dinkelborg, ...
Blood, The Journal of the American Society of Hematology 94 (1), 192-198, 1999
2661999
Monoclonal antibodies in the analysis of fibronectin isoforms generated by alternative splicing of mRNA precursors in normal and transformed human cells.
L Borsi, B Carnemolla, P Castellani, C Rosellini, D Vecchio, G Allemanni, ...
The Journal of cell biology 104 (3), 595-600, 1987
2431987
Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues
J Kaczmarek, P Castellani, G Nicolo, B Spina, G Allemanni, L Zardi
International journal of cancer 59 (1), 11-16, 1994
2051994
Phage antibodies with pan‐species recognition of the oncofoetal angiogenesis marker fibronectin ED‐B domain
B Carnemolla, D Neri, P Castellani, A Leprini, G Neri, A Pini, G Winter, ...
International journal of cancer 68 (3), 397-405, 1996
2001996
Differentiation between high-and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin
P Castellani, L Borsi, B Carnemolla, A Biro, A Dorcaratto, GL Viale, D Neri, ...
The American journal of pathology 161 (5), 1695-1700, 2002
1772002
Transforming growth factor-β regulates the splicing pattern of fibronectin messenger RNA precursor
L Borsi, P Castellani, AM Risso, A Leprini, L Zardi
FEBS letters 261 (1), 175-178, 1990
1771990
Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody
B Carnemolla, P Castellani, M Ponassi, L Borsi, S Urbini, G Nicolo, ...
The American journal of pathology 154 (5), 1345-1352, 1999
1691999
Comparative analysis of the expression of the extracellular matrix protein tenascin in normal human fetal, adult and tumor tissues
PG Natali, MR Nicotra, A Bigotti, C Botti, P Castellani, AM Risso, L Zardi
International journal of cancer 47 (6), 811-816, 1991
1681991
Transformed human cells release different fibronectin variants than do normal cells.
P Castellani, A Siri, C Rosellini, E Infusini, L Borsi, L Zardi
The Journal of cell biology 103 (5), 1671-1677, 1986
1551986
Molecular imaging of atherosclerotic plaques using a human antibody against the extra-domain B of fibronectin
CM Matter, PK Schuler, P Alessi, P Meier, R Ricci, D Zhang, C Halin, ...
Circulation research 95 (12), 1225-1233, 2004
1372004
DAMPs and inflammatory processes: the role of redox in the different outcomes
S Carta, P Castellani, L Delfino, S Tassi, R Vene, A Rubartelli
Journal of leukocyte biology 86 (3), 549-555, 2009
1352009
Redox remodeling allows and controls B-cell activation and differentiation
R Vené, L Delfino, P Castellani, E Balza, M Bertolotti, R Sitia, A Rubartelli
Antioxidants & redox signaling 13 (8), 1145-1155, 2010
1092010
Targeted Delivery of Tumor Necrosis Factor-α to Tumor Vessels Induces a Therapeutic T Cell–Mediated Immune Response that Protects the Host Against Syngeneic Tumors of Different …
E Balza, L Mortara, F Sassi, S Monteghirfo, B Carnemolla, P Castellani, ...
Clinical cancer research 12 (8), 2575-2582, 2006
1042006
The redox state of the lung cancer microenvironment depends on the levels of thioredoxin expressed by tumor cells and affects tumor progression and response to prooxidants
J Ceccarelli, L Delfino, E Zappia, P Castellani, M Borghi, S Ferrini, ...
International Journal of Cancer 123 (8), 1770-1778, 2008
1012008
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20